News by Subject
News by Disease
News by Date
Post Your News
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
US & Canada
Post an Event
News | News By Subject | News by Disease |
News By Date | Search News
AxoGen, Inc. (LECT) Announces Release Date of Third Quarter 2013 Results and Management Conference Call
10/17/2013 10:57:50 AM
Alachua, FL, October 17, 2013 – AxoGen, Inc. (NASDAQ: AXGN), a leader in the science and commercialization of surgical solutions for peripheral nerve repair, announced that it will release its financial results for the period ended September 30, 2013, after the close of U.S. financial markets on October 30, 2013.
An accompanying conference call hosted by Karen Zaderej, Chief Executive Officer, and Greg Freitag, Chief Financial Officer, to discuss the results will be held at 10:00 a.m. ET, on Thursday, October 31, 2013. Dial in information for the live call is as follows:
Conference dial-in: 877-674-2413
International dial-in: 914-495-8604
Conference Name: AxoGen, Inc. Third Quarter 2013 Results Conference Call
Conference ID: 82347276
Conference Call Webcast: www.axogeninc.com/investors.html
Following the live call, a replay will be available on the Company's website, www.AxoGenInc.com, under “Investors.”
About AxoGen, Inc.
AxoGen (NASDAQ: AXGN) is a leading regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. The Company’s innovative approach to regenerative medicine has resulted in first-in-class products that will define their product categories. AxoGen’s products offer a full suite of surgical nerve repair solutions including Avance® Nerve Graft, the only off-the-shelf commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa ExtraCellular Matrix (ECM) coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.
AxoGen is the parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGen’s principal executive office and operations are located in Alachua, FL. For more information on AxoGen and its technology, please visit www.AxoGenInc.com. To receive email alerts directly from AxoGen, please click here www.axogeninc.com/emailalerts.html.
Greg Freitag, Chief Financial Officer & General Counsel
Help employers find you! Check out all the jobs and post your resume.